<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science|2007Cited by 4.5k
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCAlexa B. Turke, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Cancer Cell|2010Cited by 1.1k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)J. Jean Cui, Martin P. Edwards, Michelle Tran‐Dubé et al.|Journal of Medicinal Chemistry|2011Cited by 924
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic MechanismsHelen Y. Zou, James G. Christensen|Cancer Research|2007Cited by 750
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met OverexpressionMark M. Awad, Lynette M. Sholl, Geoffrey R. Oxnard et al.|Journal of Clinical Oncology|2016Cited by 687